Gene therapy developer Code Biotherapeutics announced today that it launched with $10 million in seed financing. Hatfield, Pa.-based Code Biotherapeutics develops 3DNA, a proprietary synthetic DNA-based vector designed to deliver genes of all sizes to multiple cell types as a re-dosable therapy, according to a news release. The company said it is focused on developing […]
